The 5 Best Stocks (And 5 Worst) of the Coronavirus Correction

Worst #5: Mednax

• Market value: $1.4 billion
• Dividend yield: N/A
• Performance: -35.7% (vs. -12.8% for the S&P 500)
• Mednax (MD, $17.09), a medical outsourcing network of specialist physicians, has been one of the worst stocks of the coronavirus correction – but for reasons totally unrelated to COVID-19.

On Feb. 20, Dow component UnitedHealth Group (UNH) said it was canceling contracts with the company. Mednax said the UNH contracts represented 2% of its 2019 revenue. Moody's immediately put the company's credit ratings under review for a downgrade.

UnitedHealth said it's terminating the contracts because Mednax's prices are too high. That said, a few analysts pointed out that the termination of contracts won't necessarily come to pass.

"They may turn out to be a negotiating tactic by UNH, as such threatened terminations often are," writes BMO Equity Research analyst Matt Borsch.

Best #5: Etsy

• Market value: $6.8 billion
• Dividend yield: N/A
• Performance: +8.7%

Shares in Etsy (ETSY, $57.81) took off after the company delivered a beat-and-raise fourth-quarter report, fueled by a strong holiday selling season. Indeed, the online marketplace for handmade apparel and accessories posted a whopping 35% increase in revenue.

"Etsy's fourth-quarter results came in ahead of expectations and guidance, as continued platform enhancements drove strong holiday performance," writes Canaccord Genuity.

The market is also bullish on the company's introduction of its Offsite Ads feature, in which Etsy works with sites like Alphabet's (GOOGL) Google and Facebook (FB) to promote sellers' listings on their pages. Needham says the new ad service "changes the game for 2020."

It has been one of the best stocks since the start of the correction, with a nearly 9% gain while the vast majority of Russell 1000 stocks suffered losses. If consumers further avoid brick-and-mortar retail amid the outbreak, Etsy could be set up for more outperformance given its presence as an online-only retailer. However, if the coronavirus cuts deep enough into consumer spending, Etsy and its purely discretionary products would still be at risk.

Worst #4: Nutanix

• Market value: $4.6 billion
• Dividend yield: N/A
• Performance: -36.3%

Traders rushed out of Nutanix (NTNX, $23.84) after the company missed analysts' quarterly estimates. The cloud-computing company reported a loss of $1.13 a share – steeper than the loss of 68 cents in last year's second quarter. Even worse, Nutanix issued a downbeat earnings outlook.

The stock has been in a downtrend since late 2018, losing 60% since June of that year. While it rebounded somewhat during Q4 2019, the latest batch of bad news wiped out most of the recovery.

Coronavirus wasn't responsible for the loss, but it is affecting how fast the company is hiring new employees.

"We would like to have more clarity to see if there might be any further potential disruption related to the impact of the coronavirus and whether that disruption spreads to other parts of the world," CFO Duston Williams said on a conference call with analysts.

TOOL: Stimulus Check Calculator (How Much Will You Get?)

Best #4: Regeneron Pharmaceuticals

• Market value: $48.9 billion
• Dividend yield: N/A
• Performance: +10.9%

COVID-19 has been a nightmare for almost every stock in the market, but not for Regeneron Pharmaceuticals (REGN, $444.57). Indeed, only two stocks in the S&P 500 posted gains last week, and biotechnology stock REGN was the leader. (The other positive stock was chipmaker Qorvo (QRVO), which rose 2.4%.)

The spread of coronavirus has been a catalyst for REGN as the company as it scrambles to develop products aimed at the disease. "The company is working to develop treatments to fight the coronavirus," says Miller Tabak & Co. analyst Matt Maley. "That's why it's seen a nice rally."

Other analysts see additional drivers, however. Credit Suisse analyst Evan Seiger (Outperform, equivalent of Buy) raised his price target on REGN shares on Feb. 26, continuing to call it his best stock for 2020. He believes headline risk to competitor Novartis' (NVS) eye drug Beovu means good things for Regeneron's Eylea, which has a good long-term safety record.

REGN gained more than 10% during the early stages of the stock market correction and now is up nearly 19% for the year-to-date.

Worst #3: Sabre

• Market value: $3.7 billion
• Dividend yield: 4.1%
• Performance: -39.1%

Shares in air carriers, cruise line operators and other travel stocks are getting hammered by coronavirus, and Sabre (SABR, $13.62) is no exception. The company, which provides software and services to airlines, hotels and booking agents, is taking the sharp decline in global travel hard.

The company has been upfront about the harm to its business. "While we hope its impact is short-term in nature, we anticipate that the coronavirus will have a material impact on our 2020 financial results, and at this point, no one can predict the timeline and ultimate effects of the outbreak," CEO Sean Menke said on a conference call with analysts.

William Blair Equity Research, which rates shares at Market Perform (equivalent of Hold), notes that COVID-10 could impact first-quarter revenue by $100 million to $150 million. Free cash flow (the cash left over after the company spends and invests to maintain and expand its business) could be cut by $50 million to $80 million.

Best #3: Alkermes

• Market value: $3.3 billion
• Dividend yield: N/A
• Performance: +11.6%
• Alkermes (ALKS, $20.84) was one of the best stocks of the coronavirus recession's early stages, but that's about the extent of it. The biotech stock, which is developing treatments for alcohol dependence and schizophrenia, has been in a downtrend for more than two years. Heck, it's off nearly 40% over the past 52 weeks.

ALKS topped Wall Street expectations when it reported quarterly results on Feb. 13, but shares sold off on the news. "Given the adverse market reaction to an overall unsurprising quarter, it's increasingly clear that it's going to take more tangible progress to shift investor sentiment," writes JPMorgan analyst Cory Kasimov. "Unfortunately, we don't see what that trigger might be over the near-to-intermediate term, as 2020 is shaping up as a relatively quiet year."

The stock did pick up momentum a few days later, in part on news that Sarissa Capital Management LP, run by biotech activist investor Alex Denner, made a $75 million bet on the company during the fourth quarter.

Nonetheless, as welcome as ALKS's very short-term performance has been, investors might be wise not to expect sustainable gains.

Worst #2: Kosmos Energy

• Market value: $1.2 billion
• Dividend yield: 5.9%
• Performance: -41.6%

The energy sector is being hit especially hard by coronavirus because it poses a threat to everything from air travel to manufacturing.

However, oil and gas exploration company Kosmos Energy (KOS, $3.05) has more problems than just COVID-19.

In late January, Kosmos was forced to plug and abandon an exploratory well in the Gulf of Mexico that failed to find significant oil and gas deposits. And like its peers, KOS carries a lot of debt. As of the end of 2019, Kosmos has $2 billion in long-term debt versus $225 million in cash and cash equivalents.

Kosmos ended 2019 with a full-year loss of 5 cents a share. Analysts expect the company to report full-year losses of 13 cents and 5 cents this year and in 2021, respectively. For the current quarter, KOS is forecast to post a net loss of 11 cents a share on an adjusted basis. Those numbers might be acceptable for a high-growth tech IPO, but not a long-struggling energy small cap.

Best #2: Domino's Pizza

• Market value: $13.1 billion
• Dividend yield: 0.9%
• Performance: +14.3%
• Domino's Pizza (DPZ, $339.46) is one of the best stocks of the past decade, and it's flying high in 2020 as well. Shares in the pizza chain blasted off Feb. 20, rallying about 28% in a single session on a better-than-expected quarterly report. Heavy short interest in the name helped amplify the gains, as bearish traders found themselves in a short squeeze.

DPZ's outside performance had little to do with coronavirus, though its positioning as a mostly delivery-based restaurant might help its appeal among consumers hesitant to visit more crowded sit-in locations.

Valuation could be a longer-term concern, however. After gaining 50% in a little more than six months – including a pullback from that Feb. 20 rally – a number of analysts think DPZ stock is too expensive relative to its growth prospects.

"Although we remain highly confident in the near- and long-term growth outlook for the company, we believe the expectations likely embedded in the current price create a less compelling risk/reward setup," writes Stifel, which said they would prefer to be buyers on a pullback.

Worst #1: Chesapeake Energy

• Market value: $537.4 million
• Dividend yield: N/A
• Performance: -42.6%

Speaking of energy exploration companies being crushed by debt and soft prices of oil and gas, Chesapeake Energy (CHK, $0.28) – once a darling of the U.S. shale revolution – is trading like a penny stock.

CHK is off more than 90% over the past 52 weeks. For the five days ended Feb. 28, it shed more than 40% of its value, and it was booted from the S&P MidCap 400. The selling accelerated last week after Chesapeake's fourth-quarter report missed revenue expectations and gave a downbeat outlook on commodities prices. Additionally, it announced plans for a reverse stock split. With shares trading so low, CHK runs the risk of eventually being delisted.

Investors are increasingly concerned about the company's debt load. CHK carries more than $9 billion in long-term debt, and the bond market is increasingly worried about whether the company is good for it.

Chesapeake's 11.5% bonds maturing in 2025 have 28% last week to 57 cents on the dollar, Bloomberg reports. The yield on those bonds, which reflects a bond's risk, stands at almost 30%.

Best #1: Moderna

• Market value: $8.7 billion
• Dividend yield: N/A
• Performance: +37.1%

Traders are betting big-time on Moderna (MRNA, $25.93) as the biotechology firm works to develop a vaccine for COVID-19.

"On corona, our only focus as a team is public health," CEO Stéphane Bancel said on a conference call with analysts. "People are sick all over the planet. People are dying. But this is our only focus, is to get a vaccine as fast as we can safely, partnering with the right people to get it done."

MRNA blasted off in the middle of last week after it said it sent the first batch of a coronavirus vaccine to the National Institute of Allergy and Infectious Diseases. Shares quickly gave up a big chunk of those gains but still ended last week up more than 37%.